Phenytoin
- Generic Name
- Phenytoin
- Brand Names
- Dilantin, Phenytek
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12N2O2
- CAS Number
- 57-41-0
- Unique Ingredient Identifier
- 6158TKW0C5
- Background
Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.
Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects. Both parenteral and oral formulations of phenytoin are available on the market.
- Indication
Phenytoin is indicated to treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery. Injectable phenytoin and Fosphenytoin, which is the phosphate ester prodrug formulation of phenytoin, are indicated to treat tonic-clonic status epilepticus, and for the prevention and treatment of seizures occurring during neurosurgery.
- Associated Conditions
- Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Grand Mal Status Epilepticus, Jacksonian epilepsy, Partial-Onset Seizures, Petit Mal Epilepsy, Seizure Disorder, Post Traumatic, Seizures, Status; Epilepticus, Tonic-clonic, Temporal Lobe Epilepsy (TLE), Convulsive disorders
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT05995249
- Locations
- 🇺🇸
Celerion - Tempe, AZ Site, Tempe, Arizona, United States
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 65
- Registration Number
- NCT05901714
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
- Conditions
- Drug Resistant Epilepsy
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Dr Cipto Mangunkusumo General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05697614
- Locations
- 🇮🇩
Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia
🇮🇩Harapan Kita Hospital, Jakarta, Indonesia
🇮🇩Fatmawati Hospital, Jakarta, Indonesia
Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Mostafa Bahaa
- Target Recruit Count
- 90
- Registration Number
- NCT05637086
- Locations
- 🇪🇬
Mansoura University, Mansoura, Egypt
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04981704
- Locations
- 🇺🇸
Celerion, Phoenix clinical facility, Tempe, Arizona, United States
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04845646
- Locations
- 🇺🇸
ICON early Phase Services LLC, San Antonio, Texas, United States
Phenytoin Cream for the Treatment of Neuropathic Pain
- Conditions
- Chronic Idiopathic Axonal Polyneuropathy
- Interventions
- Other: Placebo cream
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- David J. Kopsky
- Target Recruit Count
- 81
- Registration Number
- NCT04647877
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Pharmacological Management of Seizures Post Traumatic Brain Injury
- Conditions
- Traumatic Brain InjuryPost Traumatic Seizures
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-11-03
- Target Recruit Count
- 1649
- Registration Number
- NCT04573803
Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus
- Conditions
- Management of Pediatric Status EpilepticusComparisonthe Efficacy of LevetireacetamPhenytoin
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04176887
- Locations
- 🇪🇬
Tanta University, Faculty of Medicine, Tanta, Gharbia, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.